{"id":"NCT00658684","sponsor":"Pfizer","briefTitle":"Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.","officialTitle":"An Open-Label, Multicenter, Long Term Study to Evaluate the Safety, Tolerability and Efficacy of Fesoterodine in Patients With Overactive Bladder.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-02","primaryCompletion":"2009-08","completion":"2009-08","firstPosted":"2008-04-15","resultsPosted":"2010-08-11","lastUpdate":"2010-10-13"},"enrollment":153,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Overactive Bladder"],"interventions":[{"type":"DRUG","name":"fesoterodine fumarate","otherNames":[]}],"arms":[{"label":"Fesoterodine fumarate","type":"EXPERIMENTAL"}],"summary":"To assess the long term safety, tolerability and efficacy of fesoterodine in patients with OAB.","primaryOutcome":{"measure":"Safety Measurement Based on Adverse Events (AEs), Vital Signs, Clinical Laboratory Test, 12-lead ECG and Residual Urine Volume","timeFrame":"52 Weeks","effectByArm":[{"arm":"Total","deltaMin":138,"sd":null},{"arm":"4 mg","deltaMin":91,"sd":null},{"arm":"4 mg > 8 mg > 4 mg","deltaMin":25,"sd":null},{"arm":"4 mg > 8 mg","deltaMin":22,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":12,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0221006&StudyName=Long%20Term%20Study%20To%20Evaluate%20the%20Safety%2C%20Tolerability%20and%20Efficacy%20of%20Fesoterodine%20for%20Overactive%20Bladder."]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":152},"commonTop":["Dry mouth","Nasopharyngitis","Constipation","Back pain","Cystitis"]}}